Abstract | BACKGROUND: METHODS: Eligible patients between 18 and 65 years with >or= 3 binge eating days/week and a body mass index (BMI) between 30 and 50 kg/m2 were randomized. RESULTS: A total of 407 patients enrolled; 13 failed to meet inclusion criteria, resulting in 195 topiramate and 199 placebo patients. Topiramate reduced binge eating days/week (-3.5 +/- 1.9 vs. -2.5 +/- 2.1), binge episodes/week (-5.0 +/- 4.3 vs. -3.4 +/- 3.8), weight (-4.5 +/- 5.1 kg vs. .2 +/- 3.2 kg), and BMI (-1.6 +/- 1.8 kg/m2 vs. .1 +/- 1.2 kg/m2) compared with placebo (p < .001). Topiramate induced binge eating remission in 58% of patients (placebo, 29%; p < .001). Discontinuation rates were 30% in each group; adverse events (AEs) were the most common reason for topiramate discontinuation (16%; placebo, 8%). Paresthesia, upper respiratory tract infection, somnolence, and nausea were the most common AEs with topiramate. CONCLUSIONS: This multicenter study in patients with BED associated with obesity demonstrated that topiramate was well tolerated and efficacious in improving the features of BED and in reducing obesity.
|
Authors | Susan L McElroy, James I Hudson, Julie A Capece, Karen Beyers, Alan C Fisher, Norman R Rosenthal, Topiramate Binge Eating Disorder Research Group |
Journal | Biological psychiatry
(Biol Psychiatry)
Vol. 61
Issue 9
Pg. 1039-48
(May 01 2007)
ISSN: 0006-3223 [Print] United States |
PMID | 17258690
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Obesity Agents
- Topiramate
- Fructose
|
Topics |
- Adult
- Anti-Obesity Agents
(adverse effects, therapeutic use)
- Body Mass Index
- Bulimia Nervosa
(complications, drug therapy, psychology)
- Double-Blind Method
- Female
- Fructose
(adverse effects, analogs & derivatives, therapeutic use)
- Humans
- Male
- Middle Aged
- Obesity
(drug therapy, etiology, psychology)
- Psychiatric Status Rating Scales
- Topiramate
- Treatment Outcome
|